New lung drug candidate shows promise in early safety study
NCT ID NCT07456800
First seen Mar 10, 2026 · Last updated May 24, 2026 · Updated 13 times
Summary
This early-stage study tested a new drug called Lyt-100 (deupirfenidone) in 116 healthy adults aged 60-80. The goal was to compare its safety and how the body processes it versus the existing drug pirfenidone. Results will help decide the best dose for future studies in patients with lung disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETIC ANALYSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Accel Research Sites
Lake Mary, Florida, 32746, United States
-
Collaborative Neuroscience Network, LLC.
Long Beach, California, 90806, United States
-
Hassman Research
Berlin, New Jersey, 08009, United States
Conditions
Explore the condition pages connected to this study.